CorMedix Announces FDA Acceptance Of Resubmission Of New Drug Application For DefenCath
Portfolio Pulse from Benzinga Newsdesk
CorMedix announced that the FDA has accepted the resubmission of its New Drug Application (NDA) for DefenCath, a novel system to predict and help prevent adverse food reactions using personal medical data. The patent also describes algorithms to determine safety levels of food ingredients, offering a personalized approach to dietary interventions and safety.
June 21, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CorMedix's FDA acceptance of the resubmitted NDA for DefenCath may positively impact the company's stock price in the short term.
The FDA's acceptance of the resubmitted NDA for DefenCath is a positive development for CorMedix, as it indicates progress in the regulatory process. This news may lead to increased investor confidence and a potential short-term increase in the stock price of CRMD.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100